| Description | RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist (IC50=63.8 nM), with improved drug-like properties[1]. |
| In vitro | RORγt inverse agonist 13 在Th17细胞分化测试中以0.3μM的浓度展现了76%的抑制效果[1]。 |
| In vivo | RORγt inverse agonist 13 在小鼠体内呈现出优异的药代动力学（PK）特性，并在IMQ诱导的银屑病小鼠模型中展现出良好的体内疗效[1]。 |
| Target activity | RORγ:63.8 nM |
| molecular weight | 513.29 |
| Molecular formula | C23H17Cl2F3N2O4 |
| CAS | 2170477-75-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 10 mg/mL (19.48 mM), Sonication is recommended. |